Trial · NCT00588146
Phase 2 Study of PEG-Intron in Hereditary Hemorrhagic Telangiectasia
NCT00588146, Phase 2, Terminated, Mayo Clinic; results first posted 2013-01-28
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Phase 2 Study of PEG-Intron in Hereditary Hemorrhagic Telangiectasia. Trials, record NCT00588146. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00588146
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Phase 2 Study of PEG-Intron in Hereditary Hemorrhagic Telangiectasia
- NCT number
- NCT00588146
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 10 participants, actual
- Lead sponsor
- Mayo Clinic
- Conditions
- Anemia, Liver Disease, Hypoxemia
- Interventions
- Pegylated Interferon Alpha2b, Standard care
- First posted
- 2008-01-08
- Last updated
- 2013-02-22
- Results first posted
- 2013-01-28
- Limitations and caveats
- The study was terminated early because Schering-Plough discontinued supplying study drug.
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Hemoglobin | baseline, one year | The hemoglobin level is expressed as the amount of hemoglobin in grams (gm) per deciliter (dL) of whole blood. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in Hemoglobin | baseline, one year | Only 3 subjects completed the study, so the numbers were too low to analyze the study. |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow12
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| First Intervention (Baseline to 6 mo) | STARTED | Pegylated Interferon Alpha2b, Then Standard Care | 5 | |
| First Intervention (Baseline to 6 mo) | STARTED | Standard Care, Then Pegylated Interferon Alpha2b | 5 | |
| First Intervention (Baseline to 6 mo) | COMPLETED | Pegylated Interferon Alpha2b, Then Standard Care | 1 | |
| First Intervention (Baseline to 6 mo) | COMPLETED | Standard Care, Then Pegylated Interferon Alpha2b | 2 | |
| First Intervention (Baseline to 6 mo) | NOT COMPLETED | Pegylated Interferon Alpha2b, Then Standard Care | 4 | |
| First Intervention (Baseline to 6 mo) | NOT COMPLETED | Standard Care, Then Pegylated Interferon Alpha2b | 3 | |
| Second Intervention (6 Months to 1 Year) | STARTED | Pegylated Interferon Alpha2b, Then Standard Care | 1 | |
| Second Intervention (6 Months to 1 Year) | STARTED | Standard Care, Then Pegylated Interferon Alpha2b | 2 | |
| Second Intervention (6 Months to 1 Year) | COMPLETED | Pegylated Interferon Alpha2b, Then Standard Care | 1 | |
| Second Intervention (6 Months to 1 Year) | COMPLETED | Standard Care, Then Pegylated Interferon Alpha2b | 2 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 participant flowAdverse events12
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Seizure | General disorders | Pegylated Interferon Alpha-2b | 0 | 10 | 0 |
| other | Seizure | General disorders | Standard Care | 1 | 10 | 1 |
| other | Depression | Psychiatric disorders | Pegylated Interferon Alpha-2b | 0 | 10 | 0 |
| other | Depression | Psychiatric disorders | Standard Care | 1 | 10 | 2 |
| other | Myalgias | Musculoskeletal and connective tissue disorders | Pegylated Interferon Alpha-2b | 1 | 10 | 1 |
| other | Myalgias | Musculoskeletal and connective tissue disorders | Standard Care | 1 | 10 | 1 |
| other | Arthralgias | Musculoskeletal and connective tissue disorders | Pegylated Interferon Alpha-2b | 1 | 10 | 1 |
| other | Arthralgias | Musculoskeletal and connective tissue disorders | Standard Care | 1 | 10 | 1 |
| other | Right flank pain | Musculoskeletal and connective tissue disorders | Pegylated Interferon Alpha-2b | 1 | 10 | 1 |
| other | Right flank pain | Musculoskeletal and connective tissue disorders | Standard Care | 0 | 10 | 0 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Pegylated Interferon Alpha-2b | ||
| Total, all-cause mortality | Standard Care | ||
| Total, other adverse events | Pegylated Interferon Alpha-2b | 2 | 10 |
| Total, other adverse events | Standard Care | 2 | 10 |
| Total, serious adverse events | Pegylated Interferon Alpha-2b | 3 | 10 |
| Total, serious adverse events | Standard Care | 0 | 10 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R01FD003076 | Phase 2 Study of PEG-Intron in Hereditary Hemorrhagic T* | SWANSON, KAREN L | MAYO CLINIC ROCHESTER | FOOD AND DRUG ADMINISTRATION | 2006 to 2008 |
Source NIH RePORTER
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Pegylated Interferon Alpha-2b vs Standard Care: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00588146
GET https://conductscience.org/api/trials/v1/NCT00588146/registered